Seasonal Influenza Vaccines
Influenza vaccines are the mainstay of efforts to reduce the substantial health burden from seasonal influenza. Inactivated influenza vaccines have been available since the 1940s and are administered via intramuscular injection. Inactivated vaccines can be given to anyone six months of age or older. Live attenuated, cold-adapted influenza vaccines (LAIV) were developed in the 1960s but were not licensed in the United States until 2003, and are administered via nasal spray. Both vaccines are trivalent preparations grown in eggs and do not contain adjuvants. LAIV is licensed for use in the United States for healthy nonpregnant persons 2–49 years of age.
Influenza vaccination induces antibodies primarily against the major surface glycoproteins hemagglutinin (HA) and neuraminidase (NA); antibodies directed against the HA are most important for protection against illness. The immune response peaks at 2–4 weeks after one dose in primed individuals. In previously unvaccinated children <9 years of age, two doses of influenza vaccine are recommended, as some children in this age group have limited or no prior infections from circulating types and subtypes of seasonal influenza. These children require both an initial priming dose and a subsequent booster dose of vaccine to mount a protective antibody response.
The most common adverse events associated with inactivated vaccines are sore arm and redness at the injection site; systemic symptoms such as fever or malaise are less commonly reported. Guillian–Barré Syndrome (GBS) was identified among approximately 1 per 100,000 recipients of the 1976 swine influenza vaccine. The risk of influenza vaccine-associated GBS from seasonal influenza vaccine is thought to be at most approximately 1–2 cases per 1 million vaccinees, based on a few studies that have found an association; other studies have found no association.
The most common adverse events associated with LAIV are nasal congestion, headache, myalgias or fever. Studies of the safety of LAIV among young children suggest an increased risk of wheezing in some young children, and the vaccine is not recommended for children younger than 2 years old, ages 2-4 old with a history of recurrent wheezing or reactive airways disease, or older persons who have any medical condition that confers an increased risk of influenza-related complications.
The effectiveness of influenza vaccines is related predominantly to the age and immune competence of the vaccinee and the antigenic relatedness of vaccine strains to circulating strains. Vaccine effectiveness in preventing laboratory-confirmed influenza illness when the vaccine strains are well matched to circulating strains is 70–90% in randomized, placebo-controlled trials conducted among children and young healthy adults, but is lower among elderly or immunocompromised persons. In years with a suboptimal match, vaccine benefit is likely to be lower, although the vaccine can still provide substantial benefit, especially against more severe outcomes. Live, attenuated influenza vaccines have been most extensively studied among children, and have been shown to be more effective than inactivated vaccines in several randomized controlled trials among young children.
Influenza vaccination is recommended in the United States for all children six months or older, all adults 50 years or older, all persons with chronic medical conditions, and pregnant women, and contacts of these persons, including healthcare workers. The global disease burden of influenza is substantial, and the World Health Organization has indicated that member states should evaluate the cost-effectiveness of introducing influenza vaccination into national immunization programs. More research is needed to develop more effective seasonal influenza vaccines that provide long-lasting immunity and broad protection against strains that differ antigenically from vaccine viruses.
KeywordsInfluenza Virus Influenza Vaccine Influenza Vaccination Influenza Season Vaccine Adverse Event Reporting System
- Anon (1944) A clinical evaluation of vaccination against influenza. JAMA 124:982–985Google Scholar
- Arden NH, Patriarca PA, Kendal AP (1986) Experiences in the use and efficacy of inactivated influenza vaccine in nursing homes. In: Kendal AP, Patriarca PA (eds) Options for the control of influenza. Alan R. Liss, New York, pp 155–168Google Scholar
- Brooks WA et al. (2007) Human metapneumovirus infection among children, Bangladesh. Emerg Infect Dis 13:1611–1613Google Scholar
- CDC (1992) Outbreak of influenza A in a nursing home—New York, December 1991–January 1992. MMWR 41:129–131Google Scholar
- CDC (2007) Update: influenza activity—United States and Worldwide, May 20–September 17, 2007. MMWR 56:1001–1004Google Scholar
- Creighton C (1891) A History of epidemics in Britain, AD 664–1666. Cambridge University Press, New YorkGoogle Scholar
- Davenport FM (1962) Current knowledge of influenza vaccine. JAMA 182:121–123Google Scholar
- Demicheli V et al. (2004) Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev CD001269Google Scholar
- Dowdle WR (1981) Influenza immunoprophylaxis after 30 years’ experience. In: Genetic variation among influenza viruses. Academic, New York, pp 525–534Google Scholar
- Fox JP et al. (1982a) Influenzavirus infections in Seattle families, 1975–1979. I. Study design, methods and the occurrence of infections by time and age. Am J Epidemiol 116:212–227Google Scholar
- Fox JP et al. (1982b) Influenzavirus infections in Seattle families, 1975–1979. II. Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness. Am J Epidemiol 116:228–242Google Scholar
- Francis T (1945) The development of the 1943 vaccination study of the Commission on Influenza. Am J Hyg 42:1–11Google Scholar
- Francis T, Salk JE, Brace WM (1946) The protective effect of vaccination against epidemic influenza B. JAMA 131:275–278Google Scholar
- Gruber WC et al. (1996) Evaluation of live attenuated influenza vaccines in children 6–18 months of age: safety, immunogenicity, and efficacy. National Institute of Allergy and Infectious Diseases, Vaccine and Treatment Evaluation Program and the Wyeth-Ayerst ca Influenza Vaccine Investigators Group. J Infect Dis 173:1313–1319PubMedGoogle Scholar
- Harper SA et al. (2009) Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical guidelines of the Infectious Diseases Society of America 48:1003–32Google Scholar
- Harris JW (1919) Influenza occurring in pregnant women: a statistical study of thirteen hundred and fifty cases. JAMA 72:978–980Google Scholar
- Hobson D et al. (1972) The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond.) 70:767–777Google Scholar
- Jefferson TO et al. (2007) Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev CD001269Google Scholar
- King JC et al. (2000) Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect Dis 181:725–728PubMedCrossRefGoogle Scholar
- Kramarz P et al. (2009) Use of oseltamivir in 12 European countires between 2002 and 2007–lack of association with the appearance of oseltamivir-resistant influenza A(H1N1) virusesGoogle Scholar
- LaMontagne Jr et al. (1983) Summary of clinical trials of inactivated influenza vaccine – 1978. Rev Infect Dis 5:723–736Google Scholar
- MedImmune (2008) Flumist (package insert). MedImmune, Gaithersburg (see http://www.medimmune.com/pdf/products/flumist_pi.pdf)
- Meijer A. et al. (2009) Oseltamivir-resistant influenza virus, Europe, 2007-08 season. Emerg Infect Dis Available from http://www.cdc.gov/EID/content/15/4/552.htm
- Moritz A et al. (1980) Studies with a cold-recombinant A/Victoria/3/75 (H3N2) virus. II. Evaluation in adult volunteers. J Infect Dis 142:857–860Google Scholar
- Neuzil KM, Jackson LA, Nelson J (2006) Immunogenicity and reactogenicity of one versus two doses of trivalent inactivated influenza vaccine in vaccine-naive 5–8-year-old children. J Infect DisGoogle Scholar
- Oya A, Nerome K (1986) Experiences with mass vaccination of young age groups with inactivated vaccines. In: Kendal AP, Patriarca PA (eds) Options for the control of influenza. Alan R. Liss, New York, pp. 183–192Google Scholar
- Salk JE, Menke WJ, Francis T (1945) A clinical, epidemiological and immunological evaluation of vaccination against epidemic influenza. Am J Hyg 42:57–93Google Scholar
- Smith NM et al. (2006a) Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55:1–42Google Scholar
- Smith S et al. (2006b) Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev CD004879Google Scholar
- Szilagyi P et al. (2008) Influenza vaccine effectiveness among children 6 to 59 months of age during two influenza seasons: a case-cohort study. Arch Med (in press)Google Scholar
- Thompson T (1852) Annals of influenza or epidemic catarrhal fever in Great Britain from 1510 to 1837. Sydenham Society, LondonGoogle Scholar
- Treanor JJ et al. (1999) Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 18:899–906PubMedCrossRefGoogle Scholar
- WHO (2005) H5N1 avian influenza: first steps towards development of a human vaccine. Wkly Epidemiol Rec 80:277–278Google Scholar
- WHO (2008) Meeting of the immunization strategic advisory group of experts, November 2007—conclusions and recommendations. Wkly Epidemiol Rec 83:1–16Google Scholar
- Williams MS, Wood JM (1993) A brief history of inactivated influenza virus vaccines. In: Hannoun C et al (eds) Elsevier, Amsterdam, pp 169–171Google Scholar